Study on the application of 0.05% cyclosporine in allergy-related dry eye

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100049498

Enrollment

Unknown

Registered

2021-08-02

Start date

2021-08-02

Completion date

Unknown

Last updated

2022-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

allergy-related dry eye

Interventions

Experimental group1:Cycloome QID+HYLO-COMODTID

Experimental group2:Cycloome QID

Control group:Patanol BID+HYLO-COMOD TID

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Patients with mild to moderate allergic conjunctivitis and dry eye age 18 to 70 years; 2. One of subjective symptoms such as dryness, foreign body sensation, burning sensation, fatigue, discomfort, vision fluctuation and BUT<=5s or Schirmer I test<=5mm/5min; 3. One of subjective symptoms such as dryness, foreign body sensation, burning sensation, fatigue, discomfort, and vision fluctuation, 5s < BUT <=10 s or 5 mm/5 min < Schirmer I test <=10 mm/5 min, and corneal and conjunctival fluorescent sodium staining positive; 4. Past history of eye allergy; 5. Symptoms of eye itching, foreign body sensation, increased conjunctival sac secretion, and at least one of the ocular surface clinical signs such as conjunctival congestion, edema, nipple, limbal Hornor-Trantas nodules and corneal epithelial lesions (excluding severe By).

Exclusion criteria

Exclusion criteria: 1. Patients whose age exceeds the inclusion criteria; 2. Patients with severe allergic conjunctivitis graded by ocular surface signs; 3. Those who have received local drug treatment within the past 1 week; 4. Those who have received systemic immunosuppressant or glucocorticoid therapy within the past 1 month; 5. Those who have undergone eye surgery within the past 3 months; 6. Patients with infectious inflammation of the eye or ocular adnexa; 7. Patients with active systemic diseases and systemic immune diseases.

Design outcomes

Primary

Measure	Time frame
Ocular Surface Disease Index Questionnaire;Clinical signs of ocular surface;tear film breakup time;Schirmer?;Corneal fluorescein sodium stain;Conjunctival Imprint Cytology;	—

Countries

China

Contacts

Public ContactYang Ruibo

Tianjin Medical University Eye Hospital

yangruibo771@163.com+86 18802295667

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026